Ampersand Capital Partners Mergers and Acquisitions Summary

Private Equity Profile

In the last 3 years, Ampersand Capital Partners has acquired 7 companies. It has also invested in 9 others.

Ampersand Capital Partners’ most common sectors for investment are life science (44%) and medical products (26%). The Firm’s most common investment types include buyout (lbo, mbo, mbi) (33%) and growth capital (30%). In total, Ampersand Capital Partners has invested in 21 US states and 5 different countries. Its largest (disclosed) acquisition occurred in 2013 when it acquired BioClinica for $123M.

In the last 3 years, Ampersand Capital Partners has exited 9 companies. The Firm’s most common exit type is trade sale (72%). Ampersand Capital Partners’ largest (disclosed) exit occurred in 2008 when it sold Talecris Biotherapeutics Holdings Corp for $3.1B.

Join Mergr to view Ampersand Capital Partners’ full profile and discover more large private equity firms just like it.

M&A Summary

  • M&A Total Activity94
    • M&A Buy Activity55
    • M&A Sell Activity39
  • Total Sectors Invested 12
  • Total Countries Invested 5
  • M&A Buy/Sell Connections 51
  • M&A Advisors 1

Ampersand Capital Partners

55 William St., Ste. 240,
Wellesley, Massachusetts 02481
United States
(781) 239-0700
www.ampersandcapital.com
info@ampersandcapital.com

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $30 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.


Investment Criteria

Sectors of Interest: Building Materials, Healthcare Services, Life Science, Medical Products, Test/Measurement Equipment

Target Transaction Types: Buyout (LBO, MBO, MBI), Growth Capital, Recapitalization, Secondary Buyout, Stake Purchase, Venture

Geographic Preferences: East US, Midwest US, South US, West US

Transaction Criteria Min Max
Target Revenue 10 100
Target EBITDA - -
Investment Size 10 30
Enterprise Value - -
values in millions of USD

M&A Summary

Buy vs Sell

Year ≤ '15 '16 '17 '18 '19 '20 T
Buy (3.6/yr) # 37 2 3 4 6 3 55
vol $161M $161M
Sell (3.4/yr) # 22 8 2 5 1 1 39
vol $3.6B $64M $702M $1.7B $6.1B
  94

Most Recent M&A

Company Date Value Type
American Laboratory Products Co. (ALPCO) 2020-09-21 - Recapitalization
Salem, New Hampshire · www.alpco.com
GeneWerk GmbH 2020-09-21 - Growth Capital
Heidelberg, Germany · www.genewerk.com
Canopy Biosciences LLC 2020-09-11 - Add-on Acquisition
St. Louis, Missouri · www.canopybiosciences.com
Tjoapack Netherlands B.V. 2020-04-21 - Buyout (LBO, MBO, MBI)
Etten-Leur, Netherlands · www.tjoapack.com
Canopy Biosciences LLC 2019-12-04 - Growth Capital
St. Louis, Missouri · www.canopybiosciences.com
Arranta Bio 2019-10-30 - Venture
Watertown, Massachusetts · www.arrantabio.com
New England Peptide, Inc. 2019-10-08 - Secondary Buyout
Gardner, Massachusetts · www.newenglandpeptide.com
N2 Biomedical 2019-06-18 - Growth Capital
Bedford, Massachusetts · www.n2bio.com
Vibalogics GmbH 2019-05-29 - Buyout (LBO, MBO, MBI)
Cuxhaven, Germany · www.vibalogics.com
Genome Diagnostics B.V. 2019-05-08 - Growth Capital
Utrecht, Netherlands · www.gendx.com
View All >>

Portfolio M&A

Company Acquired Add-On/Sale Date #
Nexelis 2018-09-04 AIT Bioscience 2020-07-22 4
Laval, Quebec · www.nexelis.com Indianapolis, Indiana · www.aitbioscience.com
Nexelis 2018-09-04 ImmunXperts SA 2020-03-04 3
Laval, Quebec · www.nexelis.com Gosselies, Belgium · www.immunxperts.com
New England Peptide, Inc. 2019-10-08 Peptides International, Inc. 2019-12-16 1
Gardner, Massachusetts · www.newenglandpeptide.com Louisville, Kentucky · www.pepnet.com
Nexelis 2018-09-04 PAIRimmune 2019-06-06 2
Laval, Quebec · www.nexelis.com Laval, Quebec · www.pairimmune.com
Nexelis 2018-09-04 Pacific Biomarkers 2018-11-19 1
Laval, Quebec · www.nexelis.com Seattle, Washington · www.pacbio.com
Genoptix, Inc. 2017-03-07 CynoGen, Inc. 2018-03-05 2
Carlsbad, California · www.genoptix.com Lake Forest, California · www.personalizedx.com
Genoptix, Inc. 2017-03-07 Rosetta Genomics Ltd. 2017-12-15 1
Carlsbad, California · www.genoptix.com Rehovot, Israel · www.rosettagenomics.com
Blue Sky Biotech, Inc. 2011-03-04 Blue Sky BioServices 2016-03-22 1
Warwick, Rhode Island · www.blueskybiotech.com Worcester, Massachusetts · www.blueskybioservices.com
Bioventus LLC 2012-05-07 BioStructures LLC 2015-11-30 2
Durham, North Carolina · www.bioventusglobal.com Durham, North Carolina · www.bioventusglobal.com
Bioventus LLC 2012-05-07 Advanced Biologics, LLC - OsteoAMP Product Line 2014-10-13 1
Durham, North Carolina · www.bioventusglobal.com , United States

M&A by Sector

Sector Current # Value All-time # Value
Life Science 10 (50%) - 24 (44%) -
Medical Products 5 (25%) 20M (100%) 14 (25%) 38M (24%)
Healthcare Services 1 (5%) - 3 (5%) -
Software 1 (5%) - 3 (5%) -
Information Technology - - 2 (4%) 123M (76%)
Chemicals - - 2 (4%) -
Consumer Products 1 (5%) - 2 (4%) -
Consumer Services - - 1 (2%) -
Manufacturing 1 (5%) - 1 (2%) -
Packaging 1 (5%) - 1 (2%) -
Semiconductors - - 1 (2%) -
Test/Measurement Equipment - - 1 (2%) -
Total 20 $20M 55 $161M

Acquisitions By Geo

State/Country Current # Value All-time # Value
United States 14 (70%) 20M (100%) 49 (89%) 161M (100%)
  Massachusetts 6 (30%) - 11 (20%) -
  California 3 (15%) 20M (100%) 10 (18%) 20M (12%)
  New Jersey - - 4 (7%) -
  Missouri - - 3 (5%) 18M (11%)
  Rhode Island 1 (5%) - 2 (4%) -
  North Carolina 1 (5%) - 2 (4%) -
  Arizona 1 (5%) - 2 (4%) -
  Minnesota - - 2 (4%) -
  New Hampshire 1 (5%) - 1 (2%) -
  Pennsylvania - - 1 (2%) 123M (76%)
  Wisconsin - - 1 (2%) -
  Washington - - 1 (2%) -
  Ohio - - 1 (2%) -
  Michigan - - 1 (2%) -
  Maryland - - 1 (2%) -
  Louisiana - - 1 (2%) -
  Indiana - - 1 (2%) -
  Georgia - - 1 (2%) -
  Florida - - 1 (2%) -
  Colorado - - 1 (2%) -
Germany 2 (10%) - 2 (4%) -
Netherlands 2 (10%) - 2 (4%) -
United Kingdom 1 (5%) - 1 (2%) -
Canada 1 (5%) - 1 (2%) -
  Quebec 1 (5%) - 1 (2%) -
Domestic 14 (70%) 20M (100%) 49 (89%) 161M (100%)
Cross-border 6 (30%) - 6 (11%) -
Total 20 $20M 55 $161M

Acquisitions by Deal Type

Type Current # Value All-time # Value
Buyout (LBO, MBO, MBI) 3 (15%) - 18 (33%) -
Growth Capital 9 (45%) 20M (100%) 16 (29%) 20M (12%)
Venture 1 (5%) - 10 (18%) 18M (11%)
Divestiture 4 (20%) - 5 (9%) -
Recapitalization 2 (10%) - 3 (5%) -
Going Private - - 1 (2%) 123M (76%)
Secondary Buyout 1 (5%) - 1 (2%) -
Special Situations/Distressed - - 1 (2%) -
Total 20 $20M 55 $161M

Exits by Deal Type

Type Total # Value
Trade Sale - Public Company 16 (41%) 5.9B (98%)
Trade Sale 13 (33%) 127M (2%)
Merger 3 (8%) -
Secondary Sale 3 (8%) -
IPO 2 (5%) -
Recapitalization 1 (3%) -
Unknown 1 (3%) -
Total 39 $6.1B

Top M&A Advisors

Legal Deals
Edwards Wildman Palmer LLP
 1

Deal Values

buy # Total
$100M to $1B 1 $123M
< $100M 2 $38M
TOTAL $161M
Largest BioClinica, Inc.
$123M (2013-03-13)
sell # Total
> $1B 2 $4.8B
$100M to $1B 5 $1.2B
< $100M 2 $76M
TOTAL $6.1B
Largest Talecris Biotherapeutics Holdings Corp
$3.1B (2008-08-12)

M&A Connections

Deals %
Acquired from
PE Firm(s)
17%
1 17%
Strategic(s)
83%
5 83%
Exited to
PE Firm(s)
12%
4 12%
Strategic(s)
88%
30 88%

Investor Summary

Size

Large

PE Assets

1.0B USD

Established

1988

Specialist/Generalist

Specialist

Leadership

Richard Charpie

Founder & Managing Partner

Herbert Hooper

Managing Partner

David Parker

General Partner

Dana Niles

Partner

David Anderson

Partner

 Subscribe to unlock this and 155,820
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
1 Week Free Trial Learn More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.0K Private Equity Firms
  • 144K M&A Transactions
  • 152K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.1K M&A Advisors
    (Investment Banks and Law Firms)
  • 45K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Mergr

Product

Company

Legal